#United States #New York #Gross Law Firm #Sana Biotechnology #NASDAQ SANA

Important Announcement for Sana Biotechnology Shareholders

On March 27, 2025, The Gross Law Firm issued a significant notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA). This announcement is especially crucial for those who purchased shares of Sana during the specified class period: from March 17, 2023, to November 4, 2024. The law firm encourages these shareholders to act promptly, as the deadline for lead plaintiff applications is set for May 20, 2025.

Background of the Case

The class action lawsuit against Sana Biotechnology arises from serious allegations that the company engaged in misleading statements regarding its financial stability and product candidates. According to the complaint, during the aforementioned class period, the defendants purportedly failed to disclose several critical issues:

1. Financial Risks: Sana was at significant risk of not having adequate funds to sustain its operations and develop its product candidates.
2. Overstated Promises: Product candidates SC291, SC379, and SG299 were claimed to be more promising than they realistically are, which misled investors about their potential.
3. Operational Cuts: To conserve cash and focus on more viable candidates, Sana was likely to decrease funding for the aforementioned products, potentially leading to layoffs.
4. Misleading Public Statements: The firm asserts that the public communications from Sana significantly overstated its financial capacity to manage ongoing operations and promote existing products.

Taking Action

Shareholders are strongly urged to step forward and register their participation in this class action case. To enroll or obtain additional details, they can fill out the loss submission form on the Gross Law Firm’s website.

Registration Link: Sana Biotechnology Loss Submission

By registering, affected shareholders will also gain access to portfolio monitoring tools that will keep them informed about the progress of the case. It’s important to note that while pursuing lead plaintiff status is encouraged, it is not mandatory to be involved in any potential recovery resulting from this lawsuit.

The Role of The Gross Law Firm

The Gross Law Firm is a nationally recognized advocacy group dedicated to protecting investor rights. Their commitment is particularly directed toward those who have suffered losses due to deceptive corporate practices. The firm plays a pivotal role in making sure publicly-listed companies adhere to ethical standards in their operations. Through their legal efforts, they aim to recover investor losses that may have been incurred due to the misleading or fraudulent activities of companies.

Next Steps for Shareholders

In conclusion, shareholders of Sana Biotechnology should not delay in registering for this important class action lawsuit. May 20, 2025, is the critical deadline that investors should keep in mind. Participating and taking action not only helps potential recovery but also reinforces accountability among publicly traded companies.

For further inquiries, shareholders can reach out to The Gross Law Firm directly at their New York office or through the contact information provided on their official website:
Contact Information:

• - Address: 15 West 38th Street, 12th Floor, New York, NY 10018
• - Email: info@grosslawfirm.com
• - Phone: (646) 453-8903

Stay informed, take the necessary actions, and ensure your rights as an investor are protected.